Date: 2013-10-28
Type of information: Services contract
Compound: use of OmniRat platform to generate antibodies against several targets selected by Merck KGaA
Company: Open Monoclonal Technology (USA) Merck KGaA, Merck Serono (Germany)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism: OmniRat® is a fully human monoclonal antibody platform based on rats.
Disease:
Details: * On October 28, 2013, EMD Serono, a subsidiary of Merck KGaA, and Open Monoclonal Technology (OMT), have announced expansion of their collaboration agreement from June 2012. Under the terms of the new agreement, EMD Serono will make an upfront payment to secure unlimited access to the OmniRat platform as well as success-based development milestones and royalties. Further details of the contract are not being disclosed.
* On July 9, 2012, Open Monoclonal Technolog has announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA. Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products. Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.
Financial terms:
Latest news:
